{
    "clinical_study": {
        "@rank": "30263", 
        "acronym": "STRENGTH", 
        "arm_group": [
            {
                "arm_group_label": "EPANOVA", 
                "arm_group_type": "Experimental", 
                "description": "Epanova + statin, once daily"
            }, 
            {
                "arm_group_label": "Corn oil", 
                "arm_group_type": "Active Comparator", 
                "description": "Corn oil + Statin"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is a randomized, double-blind, well-controlled (corn oil), parallel group design\n      that will enroll approximately 13,000 patients with hypertriglyceridemia and high risk for\n      CVD to be randomized 1:1 to either corn oil + statin or Epanova + statin, once daily, for\n      approximately 3-5 years as determined when the number of MACE outcomes is reached."
        }, 
        "brief_title": "Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia", 
        "completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)", 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Cardiovascular Diseases", 
                "Hypertriglyceridemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men or women, \u226518 years of age.\n\n          2. Patient must be on a stable diet and statin* therapy at least 4 weeks prior to\n             randomization (Visit 2) and meet the following criteria:\n\n               1. LDL-C <100 mg/dL\n\n               2. TG level \u2265200 and <500 mg/dL and HDL-C <40 mg/dL for men or HDL-C <45 mg/dL for\n                  women\n\n          3. Patient is at high risk for a future cardiovascular event if at least one of the\n             following criteria (3a, 3b or 3c)* is present via patient history, physical exam, or\n             medical records at the time of screening:\n\n               1. Any atherosclerotic CVD  as defined in protocol.\n\n               2. History of diabetes mellitus (type 1 or 2) and \u226540 years of age for men and \u226550\n                  years of age for women, plus one of the risk factors defined in protocol.\n\n               3. Male patients >50 years of age or females >60 years of age, with at least one of\n                  the risk factors defined in protocol.\n\n        Key Exclusion Criteria:\n\n        1.  Allergy or intolerance to omega-3 carboxylic acids, omega-3 fatty acids, omega-3-acid\n        ethyl esters, or corn oil. 2.Use of fibrates, bile acid sequestrants, or niacin or its\n        analogues (>250 mg/day) within 4 weeks prior to Visit 2.  3.Statin na\u00efve at Visit 1."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28890", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02104817", 
            "org_study_id": "D5881C00004", 
            "secondary_id": "2014-001069-28"
        }, 
        "intervention": [
            {
                "arm_group_label": "EPANOVA", 
                "description": "Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)", 
                "intervention_name": "Epanova\u00ae (omega-3 carboxylic acids)", 
                "intervention_type": "Drug", 
                "other_name": "omega-3 carboxylic acids"
            }, 
            {
                "arm_group_label": "Corn oil", 
                "description": "corn oil control arm", 
                "intervention_name": "corn oil control", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 9, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "ClinicalTrialTransparency@astrazeneca.com"
        }, 
        "overall_official": [
            {
                "affiliation": "The Cleveland Clinic", 
                "last_name": "Steven Nissen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Cleveland Clinic", 
                "last_name": "Michael Lincoff, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Adelaide Clinical Research", 
                "last_name": "Stephen Nicholls, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "MACE components include: (cardiovascular death, nonfatal MI, nonfatal stroke, emergent/elective coronary revascularization, or hospitalization for unstable angina)", 
            "measure": "The primary outcome measure is the time to the first occurrence of any component of the composite of MACE.", 
            "safety_issue": "No", 
            "time_frame": "Patients will remain in the study until the required number of MACE has occurred. We anticipate that patients will be in the study for up to 5 years."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02104817"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The secondary outcome measures will be analyzed the same as outlined above for the primary outcome measures.", 
                "measure": "The first occurrence of any component of cardiovascular death, nonfatal MI, or nonfatal stroke", 
                "safety_issue": "No", 
                "time_frame": "We anticipate that patients will be in the study for up to 5 years.  Same for all outcome measures."
            }, 
            {
                "measure": "The composite measure of coronary events that include the first occurrence of cardiovascular death, nonfatal MI, emergent/elective coronary revascularization, or hospitalization for unstable angina.", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "The first occurrence of individual components of MACE: emergent/elective coronary revascularization, hospitalization for unstable angina, fatal or nonfatal MI, fatal or nonfatal stroke, cardiovascular death.", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "\"All cause mortality\" is defined in the protocol as \"death from any cause\".", 
                "measure": "All cause mortality", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "The Cleveland Clinic", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}